Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISR's Cash-to-Debt is ranked higher than
94% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ISR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.91
ISR's Equity-to-Asset is ranked higher than
98% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. ISR: 0.91 )
Ranked among companies with meaningful Equity-to-Asset only.
ISR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.18  Med: 0.84 Max: 0.92
Current: 0.91
-1.18
0.92
Interest Coverage No Debt
ISR's Interest Coverage is ranked higher than
93% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.88 vs. ISR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISR' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 8.29
Beneish M-Score: -1.04
WACC vs ROIC
15.16%
-75.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -127.26
ISR's Operating Margin % is ranked lower than
88% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. ISR: -127.26 )
Ranked among companies with meaningful Operating Margin % only.
ISR' s Operating Margin % Range Over the Past 10 Years
Min: -169.05  Med: -100.34 Max: -56.56
Current: -127.26
-169.05
-56.56
Net Margin % -120.33
ISR's Net Margin % is ranked lower than
85% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. ISR: -120.33 )
Ranked among companies with meaningful Net Margin % only.
ISR' s Net Margin % Range Over the Past 10 Years
Min: -167.39  Med: -92.01 Max: -54.25
Current: -120.33
-167.39
-54.25
ROE % -32.94
ISR's ROE % is ranked lower than
76% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.98 vs. ISR: -32.94 )
Ranked among companies with meaningful ROE % only.
ISR' s ROE % Range Over the Past 10 Years
Min: -75.03  Med: -46.81 Max: -16.5
Current: -32.94
-75.03
-16.5
ROA % -29.50
ISR's ROA % is ranked lower than
79% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. ISR: -29.50 )
Ranked among companies with meaningful ROA % only.
ISR' s ROA % Range Over the Past 10 Years
Min: -60.54  Med: -40 Max: -14.86
Current: -29.5
-60.54
-14.86
ROC (Joel Greenblatt) % -117.46
ISR's ROC (Joel Greenblatt) % is ranked lower than
78% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. ISR: -117.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -365.49  Med: -87.14 Max: -33.47
Current: -117.46
-365.49
-33.47
3-Year Revenue Growth Rate -12.80
ISR's 3-Year Revenue Growth Rate is ranked lower than
82% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. ISR: -12.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.7
Current: -12.8
0
12.7
3-Year EBITDA Growth Rate -5.40
ISR's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. ISR: -5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26.4 Max: 401.3
Current: -5.4
0
401.3
3-Year EPS without NRI Growth Rate -6.50
ISR's 3-Year EPS without NRI Growth Rate is ranked lower than
69% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ISR: -6.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.7 Max: 278
Current: -6.5
0
278
GuruFocus has detected 3 Warning Signs with IsoRay Inc $ISR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISR's 10-Y Financials

Financials (Next Earnings Date: 2017-05-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ISR Guru Trades in Q1 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q2 2016

ISR Guru Trades in Q2 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q3 2016

ISR Guru Trades in Q3 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q4 2016

ISR Guru Trades in Q4 2016

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:AMEX:RVP, NAS:CASM, AMEX:DXR, AMEX:MLSS, NAS:BLFS, OTCPK:TSNLF, AMEX:INFU, NAS:ATEC, OTCPK:LDSYF, NAS:PDEX, OTCBB:NEPH, NAS:BMRA, OTCPK:REPR, NAS:LENS, OTCPK:IGAP, OTCPK:STXS, NAS:SKLN, OTCPK:UEEC, OTCPK:VPTDF, NAS:AKER » details
Traded in other countries:AAJ.Germany,
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes. The Company treats Brain cancer, Head & Neck cancer, Lung cancer, Colon cancer, Ocular cancer, Gynecologic cancer and Prostate cancer using Cesium-131.

IsoRay Inc was organized under Minnesota law in 1983. The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. In 2003, the Company obtained clearance from the FDA for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer; and pancreatic cancer. The brachytherapy seed form of Cesium-131 may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. In March 2011, the Company received clearance to commercially deliver Proxcelan Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands into Europe. Its products include Proxcelan Cesium-131, GliaSite RTS is the only FDA cleared balloon catheter device used in the treatment of brain cancer. The GliaSite RTS and the Company's brachytherapy products used in non-prostate applications typically compete with external beam radiation therapy (EBRT), which can be provided as conventional or intensity modulated radiation therapy, or as stereotactic radiosurgery, a technique that delivers high doses of radiation to a target in a much lower number of sessions than other forms of EBRT. The Company's present and future activities in the development, manufacture and sale of cancer therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines.

Ratios

vs
industry
vs
history
PB Ratio 2.55
ISR's PB Ratio is ranked higher than
60% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. ISR: 2.55 )
Ranked among companies with meaningful PB Ratio only.
ISR' s PB Ratio Range Over the Past 10 Years
Min: 0.31  Med: 3.51 Max: 23.68
Current: 2.55
0.31
23.68
PS Ratio 7.78
ISR's PS Ratio is ranked lower than
84% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. ISR: 7.78 )
Ranked among companies with meaningful PS Ratio only.
ISR' s PS Ratio Range Over the Past 10 Years
Min: 0.58  Med: 5.75 Max: 64.29
Current: 7.78
0.58
64.29
Current Ratio 15.13
ISR's Current Ratio is ranked higher than
98% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. ISR: 15.13 )
Ranked among companies with meaningful Current Ratio only.
ISR' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 7.09 Max: 24.59
Current: 15.13
0.82
24.59
Quick Ratio 14.69
ISR's Quick Ratio is ranked higher than
98% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. ISR: 14.69 )
Ranked among companies with meaningful Quick Ratio only.
ISR' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 6.58 Max: 24.21
Current: 14.69
0.68
24.21
Days Inventory 33.96
ISR's Days Inventory is ranked higher than
93% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. ISR: 33.96 )
Ranked among companies with meaningful Days Inventory only.
ISR' s Days Inventory Range Over the Past 10 Years
Min: 29.03  Med: 39.96 Max: 64.02
Current: 33.96
29.03
64.02
Days Sales Outstanding 51.68
ISR's Days Sales Outstanding is ranked higher than
71% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.07 vs. ISR: 51.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.3  Med: 62.07 Max: 83.11
Current: 51.68
46.3
83.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.70
ISR's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. ISR: -16.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -110.2  Med: -16.7 Max: 0
Current: -16.7
-110.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.30
ISR's Price-to-Net-Cash is ranked higher than
83% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.38 vs. ISR: 6.30 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 7.44 Max: 157.5
Current: 6.3
1
157.5
Price-to-Net-Current-Asset-Value 3.00
ISR's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.51 vs. ISR: 3.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.71  Med: 5.76 Max: 175
Current: 3
0.71
175
Price-to-Tangible-Book 2.52
ISR's Price-to-Tangible-Book is ranked higher than
67% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.31 vs. ISR: 2.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 3.69 Max: 71.78
Current: 2.52
0.35
71.78
Price-to-Median-PS-Value 1.34
ISR's Price-to-Median-PS-Value is ranked lower than
65% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ISR: 1.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.02 Max: 34.29
Current: 1.34
0.11
34.29
Earnings Yield (Greenblatt) % -19.42
ISR's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. ISR: -19.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.42  Med: 575.5 Max: 16057.5
Current: -19.42
-19.42
16057.5

More Statistics

Revenue (TTM) (Mil) $4.43
EPS (TTM) $ -0.11
Beta1.70
Short Percentage of Float4.18%
52-Week Range $0.48 - 1.30
Shares Outstanding (Mil)55.02

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 7 10 15
EPS ($) -0.02 0.01 0.07
EPS without NRI ($) -0.02 0.01 0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ISR

Headlines

Articles On GuruFocus.com
IsoRay Inc. Reports Operating Results (10-K) Sep 28 2010 
IsoRay Inc. Reports Operating Results (10-Q) May 12 2010 
IsoRay Inc. Reports Operating Results (10-Q) Nov 12 2009 
IsoRay Inc. Reports Operating Results (10-Q/A) Sep 02 2009 
IsoRay Inc. Reports Operating Results (10-Q) Aug 14 2009 

More From Other Websites
ETFs with exposure to IsoRay, Inc. : March 27, 2017 Mar 27 2017
IsoRay, Inc. :ISR-US: Earnings Analysis: Q2, 2017 By the Numbers : March 21, 2017 Mar 21 2017
ISORAY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 10 2017
IsoRay Announces Final Court Approval of Class Action Settlement Mar 09 2017
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Mar 03 2017
ISORAY, INC. Financials Feb 15 2017
ISORAY, INC. Files SEC form 10-Q, Quarterly Report Feb 09 2017
IsoRay reports 2Q loss Feb 08 2017
IsoRay reports 2Q loss Feb 08 2017
ISORAY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 08 2017
IsoRay Announces Second Quarter Fiscal 2017 Financial Results Feb 08 2017
MicroCap Review Magazine Winter/Spring 2017 Issue Now Available Feb 07 2017
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification... Feb 03 2017
IsoRay, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 02 2017
ISORAY, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers Jan 23 2017
ETFs with exposure to IsoRay, Inc. : January 19, 2017 Jan 19 2017
ISORAY, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 17 2017
Purcell Julie & Lefkowitz LLP Is Investigating IsoRay, Inc. for Potential Breaches Of Fiduciary Duty... Jan 11 2017
ETFs with exposure to IsoRay, Inc. : January 6, 2017 Jan 06 2017
ISORAY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Dec 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)